Cargando…
Evaluation of the Safety and Effectiveness of Add-On Tacrolimus in Patients with Rheumatoid Arthritis Who Failed to Show an Adequate Response to Biological DMARDs: The Interim Results of a Specific Drug Use-Results Survey of Tacrolimus
BACKGROUND: Tacrolimus (TAC) is an immunosuppressive macrolide that blocks T-cell activation by specifically inhibiting calcineurin. TAC was approved in Japan for the treatment of rheumatoid arthritis (RA) in 2005. However, the safety and effectiveness of TAC adding on to biological disease-modifyin...
Autores principales: | Ishida, Kota, Shiraki, Katsuhisa, Yoshiyasu, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662943/ https://www.ncbi.nlm.nih.gov/pubmed/26386566 http://dx.doi.org/10.1007/s40268-015-0106-8 |
Ejemplares similares
-
An interaction between tacrolimus and pristinamycin resulting in an elevated tacrolimus level
por: Tehan, Jane V., et al.
Publicado: (2011) -
Does the Tacrolimus Trough Level Adequately Predict Drug Exposure in Patients Requiring a High Tacrolimus Dose?
por: Haverals, Lien, et al.
Publicado: (2023) -
Tacrolimus: COVID-19 and toxic levels of tacrolimus: case report
Publicado: (2021) -
Tacrolimus-induced gingival hyperplasia and recovery from tacrolimus to everolimus switching
por: Oral, Alihan, et al.
Publicado: (2019) -
Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus
por: Migita, Kiyoshi, et al.
Publicado: (2015)